Mylan soars on FDA OK

Mylan’s long-awaited US approval for its generic version of Teva’s blockbuster multiple sclerosis treatment Copaxone drove Mylan’s shares up 16 percent, to $37.80.

The approval late on Tuesday by the FDA came earlier than both companies had expected.

Teva’s stock fell 15 percent, to $16.08.